Ciloxan review

Ciloxan, also known generically as ciprofloxacin (INN), is a synthetic chemotherapeutic drug and ophthalmic ointment used to treat severe, life-threatening bacterial infections in the eyes. Ciprofloxacin is usually referred to as a fluoroquinolone or quinolone drug, and is categorized under the fluoroquinolone class of antibacterials. Ciloxan as a brand is distributed worldwide, and there are well over three hundred different ciprofloxacin-based brands aside from Ciloxan available in the market today. In fact, it is also available for limited veterinary use as well.

Ciprofloxacin was first patented in 1983 by Bayer A.G. and was later approved by the US Food and Drug Administration or FDA for use in the United States in 1987 for treatment of bacterial infections that are fatal and grave. Ciprofloxacin-based products are available in liquid form, ointment form, solution form, suspension form, tablet form, combined release tablet form, and extended release tablet form. On the other hand, Ciloxan itself is exclusively an ophthalmic solution or an eye drop product.

In regards to dosage, apply a half inch ribbon into the conjunctival sac three times daily on the first two days, and then apply a half-inch ribbon two times a day for the next five days. Ciloxan eye drops and eye ointment are typically administered into the eye to treat a variety of bacterial eye infections. Using them directly into the eye allows the medicine to act right on the bacteria that are causing the infection.

Also, unless your physician advises you otherwise, it's important that you finish the prescribed treatment of this antibiotic drug even if it seems that the infection has already cleared up. Halting the therapy early increases the chance of infection relapse and that the bacteria will grow resistant to the medicine.

The licensed uses for ciprofloxacin in the United States in general are quite limited because the drug is considered a last resort when all other antibiotics have failed. Nevertheless, there consist ten approved uses in the adult population, among which are Ciloxan eye drops used to effectively remove bacterial eye infection as quickly and smoothly as possible. In any case, a patient should be aware that Ciloxan-brand ophthalmic ointments—or any other ciprofloxacin-based eye medicine—may cause visual blurring and retard corneal healing.

In addition, acute and infrequently fatal hypersensitivity or anaphylactic reactions—sometimes following the first dose—have been reported in patients receiving quinolone therapy. Some reactions were complemented by itching, urticaria, dyspnea, pharyngeal or facial edema, tingling, loss of consciousness, and cardiovascular collapse. A scant number of patients also reported a history of hypersensitivity reactions.

Acute anaphylactic response need prompt emergency medical treatment with resuscitation measures like epinephrine, corticosteroids, intravenous fluids and antihistamines, pressor amines, oxygen, and airway management as clinically specified. Lengthy or prolonged use of Ciloxan, just like with other antibacterial preparations, may result in overgrowth of nonsuscpetible organisms, including fungi.

If ever superinfection occurs, appropriate measures should be initiated and your doctor should be consulted for immediate assistance. Depending on your physician's clinical judgment, a superinfected patient could be examined with fluorescein eye staining and the aid of magnification, such as a slit lamp biomicroscopy. Finally, the drug should be stopped at the first appearance of skin rash or any other sign of allergy or hypersensitive reaction.

According to clinical studies, discomfort and keratopathy were reported to happen in patients taking Ciloxan. Other rare reactions associated with this drug occurring in less than 1% of patients include tearing, pruritus, photophobia, lid margin hyperemia, lid erythema, keratopathy, keratoconjunctivitis, irritation, hyperemia, foreign body sensation, eye pain, epitheliopathy, edema, dry eye, decreased visual acuity, corneal staining, blurred vision, and symptoms of allergy. Systemic adverse reactions to Ciloxan at an incidence below 1% included taste perversion, nausea, and dermatitis.

Ciloxan has the following structural formula:

Chemical structure of ciloxan

• Molecular formula of ciloxan is C17H18FN3O3
• Chemical IUPAC Name is 1-cyclopropyl-6-fluoro-4-oxo-7-piperazin-1-yl-quinoline-3-carboxylic acid
• Molecular weight is 331.342 g/mol
Ciloxan available : 0.3% solution 10ml bottle, 0.3% solution 2.5ml bottle, 0.3% solution 5ml bottle, 250mg tablets, 500mg tablets, 750mg tablets

Generic name: Ciprofloxacin

Brand name(s): Bacquinor, Baycip, Bernoflox, Ciflox, Cifloxin, Ciprinol, Cipro, Ciprobay, Ciprocinol, Ciprodar, Ciprodex, Ciprofloxacina, Cipromycin, Ciproquinol, Ciproxan, Ciproxin, Flociprin, Floxin, Ocuflox, Ofloxacin, Septicide, Velomonit

  Your Ciloxan review